↓ Skip to main content

Anti‐IgE therapy for IgE‐mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells

Overview of attention for article published in Clinical and Translational Allergy, July 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#35 of 743)
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
47 X users
patent
1 patent
facebook
2 Facebook pages

Citations

dimensions_citation
45 Dimensions

Readers on

mendeley
117 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti‐IgE therapy for IgE‐mediated allergic diseases: from neutralizing IgE antibodies to eliminating IgE+ B cells
Published in
Clinical and Translational Allergy, July 2018
DOI 10.1186/s13601-018-0213-z
Pubmed ID
Authors

Jiayun Hu, Jiajie Chen, Lanlan Ye, Zelang Cai, Jinlu Sun, Kunmei Ji

Abstract

Allergic diseases are inflammatory disorders that involve many types of cells and factors, including allergens, immunoglobulin (Ig)E, mast cells, basophils, cytokines and soluble mediators. Among them, IgE plays a vital role in the development of acute allergic reactions and chronic inflammatory allergic diseases, making its control particularly important in the treatment of IgE-mediated allergic diseases. This review provides an overview of the current state of IgE targeted therapy development, focusing on three areas of translational research: IgE neutralization in blood; IgE-effector cell elimination; and IgE+ B cell reduction. IgE-targeted medicines such as FDA approved drug Xolair (Omalizumab) represent a promising avenue for treating IgE-mediated allergic diseases given the pernicious role of IgE in disease progression. Additionally, targeted therapy for IgE-mediated allergic diseases may be advanced through cellular treatments, including the modification of effector cells.

X Demographics

X Demographics

The data shown below were collected from the profiles of 47 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 117 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 117 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 23 20%
Student > Master 13 11%
Student > Ph. D. Student 11 9%
Researcher 9 8%
Student > Postgraduate 7 6%
Other 19 16%
Unknown 35 30%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 20 17%
Medicine and Dentistry 20 17%
Immunology and Microbiology 11 9%
Agricultural and Biological Sciences 8 7%
Chemistry 7 6%
Other 15 13%
Unknown 36 31%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 31. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 June 2023.
All research outputs
#1,244,875
of 25,069,047 outputs
Outputs from Clinical and Translational Allergy
#35
of 743 outputs
Outputs of similar age
#26,185
of 334,914 outputs
Outputs of similar age from Clinical and Translational Allergy
#3
of 13 outputs
Altmetric has tracked 25,069,047 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 743 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 334,914 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.